ABSTRACT
Rift Valley fever (RVF) is a mosquito-borne zoonotic viral disease endemic to Africa and the Middle East. Live-attenuated RVF vaccines have been studied for both veterinary and human use due to their strong immunogenicity and cost-effective manufacturing. The live-attenuated MP-12 vaccine has been conditionally approved for veterinary use in the U.S.A., and next-generation live-attenuated RVF vaccine candidates are being actively researched. Assessing the virulence phenotype of vaccine seeds or lots is crucial for managing vaccine safety. Previously, preweaning 19-day-old outbred CD1 mice have been used to evaluate the MP-12 strain. This study aimed to characterize the relative virulence of three live-attenuated RVF vaccine strains in 19-day-old inbred C57BL/6 mice: the recombinant MP-12 (rMP-12), the RVax-1, and the ∆NSs-∆NSm-rZH501 strains. Although this mouse model did not show dose-dependent pathogenesis, mice that succumbed to the infection exhibited distinct brain pathology. Mice infected with ∆NSs-∆NSm-rZH501 showed an infiltration of inflammatory cells associated with infected neurons, and focal lesions formed around virus-infected cells. In contrast, mice infected with rMP-12 or RVax-1 showed a minimal association of inflammatory cells in the brain, yet the virus spread diffusely. The preweaning model is likely useful for evaluating host responses to attenuated RVFV strains, although further refinement may be necessary to quantitate the virulence among different RVFV strains or vaccine lots.
Subject(s)
Disease Models, Animal , Mice, Inbred C57BL , Rift Valley Fever , Rift Valley fever virus , Vaccines, Attenuated , Viral Vaccines , Animals , Rift Valley fever virus/pathogenicity , Rift Valley fever virus/immunology , Rift Valley fever virus/genetics , Rift Valley Fever/virology , Rift Valley Fever/pathology , Rift Valley Fever/prevention & control , Rift Valley Fever/immunology , Mice , Vaccines, Attenuated/immunology , Vaccines, Attenuated/administration & dosage , Viral Vaccines/immunology , Viral Vaccines/administration & dosage , Virulence , FemaleABSTRACT
Single-domain antibodies, referred to as VHH (variable heavy chains of heavy chain-only antibodies) or in their commercial name as nanobodies, are potent tools for the detection of target proteins in biological samples. They have the advantage of being highly stable, specific, and sensitive, with affinities reaching the nanomolar range. We utilized this tool to develop a rapid detection method that discriminates cells infected with Rift Valley fever virus (RVFV), based on the intracellular detection of the viral nonstructural NSm protein localized on the outer membrane of mitochondria. Here we describe how NSm-specific VHHs have been produced, cloned, and characterized, highlighting their value in RVFV research and diagnosis. This work may also raise interest in other potential applications such as antiviral therapy.
Subject(s)
Rift Valley Fever , Rift Valley fever virus , Single-Domain Antibodies , Viral Nonstructural Proteins , Rift Valley fever virus/immunology , Single-Domain Antibodies/immunology , Humans , Rift Valley Fever/immunology , Rift Valley Fever/diagnosis , Rift Valley Fever/virology , Viral Nonstructural Proteins/immunology , Animals , Antibodies, Viral/immunologyABSTRACT
Rift Valley fever (RVF) caused by Rift Valley fever virus (RVFV) is a major health concern for both domesticated animals and humans in certain endemic areas of Africa. With changing environmental conditions and identification of vectors capable of transmitting the virus, there is high risk of RVFV spreading into other parts of the world. Furthermore, unavailability of effective vaccines in the event of an outbreak can be a major challenge as witnessed recently in case of SARS-CoV2 pandemic. Hence, identifying potential vaccines and testing their protective efficacy in preclinical models before clinical testing is the absolute need of the hour. Here, we describe methods used to quantify virus-specific T cell responses in mice that were immunized with RVFV strains or antigens.
Subject(s)
Rift Valley fever virus , T-Lymphocytes , Viral Vaccines , Animals , Mice , T-Lymphocytes/immunology , Rift Valley fever virus/immunology , Viral Vaccines/immunology , Rift Valley Fever/immunology , Rift Valley Fever/prevention & control , Immunization/methods , Vaccination/methods , Antigens, Viral/immunologyABSTRACT
Rift Valley fever (RVF) is a mosquito-borne zoonotic disease caused by RVF virus (RVFV). RVFV infections in humans are usually asymptomatic or associated with mild febrile illness, although more severe cases of haemorrhagic disease and encephalitis with high mortality also occur. Currently, there are no licensed human vaccines available. The safety and efficacy of a genetically engineered four-segmented RVFV variant (hRVFV-4s) as a potential live-attenuated human vaccine has been tested successfully in mice, ruminants, and marmosets though the correlates of protection of this vaccine are still largely unknown. In the present study, we have assessed hRVFV-4s-induced humoral and cellular immunity in a mouse model of RVFV infection. Our results confirm that a single dose of hRVFV-4s is highly efficient in protecting naïve mice from developing severe disease following intraperitoneal challenge with a highly virulent RVFV strain and data show that virus neutralizing (VN) serum antibody titres in a prime-boost regimen are significantly higher compared to the single dose. Subsequently, VN antibodies from prime-boost-vaccinated recipients were shown to be protective when transferred to naïve mice. In addition, hRVFV-4s vaccination induced a significant virus-specific T cell response as shown by IFN-γ ELISpot assay, though these T cells did not provide significant protection upon passive transfer to naïve recipient mice. Collectively, this study highlights hRVFV-4s-induced VN antibodies as a major correlate of protection against lethal RVFV infection.
Subject(s)
Antibodies, Neutralizing , Antibodies, Viral , Rift Valley Fever , Rift Valley fever virus , Vaccines, Attenuated , Viral Vaccines , Animals , Rift Valley fever virus/immunology , Rift Valley fever virus/genetics , Rift Valley Fever/prevention & control , Rift Valley Fever/immunology , Viral Vaccines/immunology , Viral Vaccines/administration & dosage , Mice , Antibodies, Viral/blood , Antibodies, Viral/immunology , Antibodies, Neutralizing/blood , Antibodies, Neutralizing/immunology , Female , Vaccines, Attenuated/immunology , Vaccines, Attenuated/administration & dosage , Disease Models, Animal , Immunity, Cellular , T-Lymphocytes/immunology , Immunity, Humoral , Mice, Inbred BALB C , Interferon-gamma/immunology , VaccinationABSTRACT
INTRODUCTION: This immunoinformatic study identified potential epitopes from the envelopment polyprotein (Gn/Gc) of Rift Valley fever virus (RVFV), a pathogenic virus causing severe fever in humans and livestock. Effective vaccination is crucial for controlling RVFV outbreaks. The identification of suitable epitopes is crucial for the development of safe and effective vaccines. METHODOLOGY: Protein sequences were obtained from the UniProt database, and evaluated through VaxiJen v2.0 to predict the B and T-cell epitopes within the RVFV glycoprotein. Gn/Gc protein sequences were analyzed with bioinformatics tools and algorithms. The predicted T-cell and B-cell epitopes were evaluated for antigenicity, allergenicity, and toxicity by the VaxiJen v2.0 system, AllerTop v2.0, and ToxinPred server, respectively. RESULTS: We employed computational methods to screen the RVFV envelopment polyprotein encompassing N-terminal and C-terminal glycoprotein segments, to discover antigenic T- and B-cell epitopes. Our analysis unveiled multiple potential epitopes within the RVFV glycoprotein, specifically within the Gn/Gc protein sequences. Subsequently, we selected eleven cytotoxic T-lymphocytes (CTL) and four helper T-lymphocytes (HTL) for population coverage analysis, which collectively extended to cover 97.04% of the world's population, representing diverse ethnicities and regions. Notably, the CTL epitope VQADLTLMF exhibited binding affinity to numerous human leukocyte antigen (HLA) alleles. The identification of glycoprotein (Gn/Gc) epitopes through this immunoinformatic study bears significant implications for advancing the development of an effective RVFV vaccine. CONCLUSIONS: These findings provide valuable insights into the immunological aspects of the disease and may contribute towards the development of broad-spectrum antiviral therapies targeting other RNA viruses with similar polymerase enzymes.
Subject(s)
Computational Biology , Epitopes, B-Lymphocyte , Epitopes, T-Lymphocyte , Rift Valley fever virus , Rift Valley fever virus/immunology , Epitopes, T-Lymphocyte/immunology , Epitopes, B-Lymphocyte/immunology , Humans , Viral Vaccines/immunology , Rift Valley Fever/prevention & control , Rift Valley Fever/immunology , AnimalsABSTRACT
During the past 2 decades, several countries in Africa and the Arabian Peninsula, to which Rift Valley fever virus (RVFV) is endemic, have reported outbreaks of Rift Valley fever in humans and livestock. The first evidence of RVFV in Mozambique was documented as early as the 1960s (1). Endemicity was subsequently confirmed in the 1980s by a prevalence study that identified virusspecific antibodies in 2% of pregnant women (2) and in the 1990s by serosurveillance in Zambezia Province, which showed that cattle had been infected with RVFV.